Cerovive
| Title | Journal |
|---|---|
| To serve and neuroprotect. | Nature medicine 20120706 |
| Neuroprotection for ischaemic stroke: translation from the bench to the bedside. | International journal of stroke : official journal of the International Stroke Society 20120701 |
| Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics. | Future medicinal chemistry 20120601 |
| Neuroprotection for stroke: current status and future perspectives. | International journal of molecular sciences 20120101 |
| Anti-adrenergic medications and edema development after intracerebral hemorrhage. | Neurocritical care 20110601 |
| Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. | International journal of stroke : official journal of the International Stroke Society 20091201 |
| Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study. | Brain research 20091019 |
| Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. | British journal of pharmacology 20090801 |
| Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice. | British journal of pharmacology 20090801 |
| Scope of preclinical testing versus quality control within experiments. | Stroke 20090701 |
| Serendipitous findings while researching oxygen free radicals. | Free radical biology & medicine 20090415 |
| Cosmic implications of NXY-059. | Stroke 20090301 |
| Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. | Stroke 20090201 |
| The nitrone free radical scavenger NXY-059 is neuroprotective when administered after traumatic brain injury in the rat. | Journal of neurotrauma 20081201 |
| Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers. | Clinical therapeutics 20081201 |
| Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. | Stroke 20081001 |
| NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. | Stroke 20080601 |
| Antithrombotic and thrombolytic therapy for ischemic stroke. | Cardiology clinics 20080501 |
| A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke. | Stroke 20080401 |
| [Development of new stroke therapies: outlook for neuroprotective drugs]. | Der Nervenarzt 20080201 |
| Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. | Current cardiology reports 20080201 |
| The nitrone disodium 2,4-sulphophenyl-N-tert-butylnitrone is without cytoprotective effect on sodium nitroprusside-induced cell death in N1E-115 neuroblastoma cells in vitro. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080101 |
| Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080101 |
| The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro. | British journal of pharmacology 20080101 |
| Comments regarding the recent OAST article. | Stroke 20080101 |
| The 2007 Feinberg lecture: a new road map for neuroprotection. | Stroke 20080101 |
| A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. | Brain research 20071205 |
| Neuroprotection in the SAINT-II aftermath. | Annals of neurology 20071201 |
| NXY-059 for the treatment of stroke. | The New England journal of medicine 20071122 |
| Life after SAINT. | International journal of stroke : official journal of the International Stroke Society 20071101 |
| SAINT-I worked, but the neuroprotectant is not NXY-059. | Stroke 20071001 |
| Investigating the free radical trapping ability of NXY-059, S-PBN and PBN. | Free radical research 20070901 |
| Advances in hemorrhagic stroke therapy: conventional and novel approaches. | Expert opinion on emerging drugs 20070901 |
| NXY-059 for the treatment of acute ischemic stroke. | The New England journal of medicine 20070809 |
| Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. | Stroke 20070801 |
| A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects. | Current medical research and opinion 20070801 |
| A study of organic acid transporter mediated pharmacokinetic interaction between NXY-059 and cefuroxime. | Journal of clinical pharmacology 20070801 |
| Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects. | Current medical research and opinion 20070701 |
| Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter. | Journal of clinical pharmacology 20070701 |
| Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. | Stroke 20070601 |
| Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability. | Stroke 20070501 |
| A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. | Experimental neurology 20070501 |
| NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study. | Journal of clinical pharmacology 20070201 |
| Stroke: the dashed hopes of neuroprotection. | The Lancet. Neurology 20070101 |
| Neuroprotective effects of free radical scavengers in stroke. | Drugs & aging 20070101 |
| Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. | Stroke 20061201 |
| Translational vehicles for neuroprotection. | Biochemical Society transactions 20061201 |
| NXY-059 does not significantly interact with furosemide in healthy volunteers. | Journal of clinical pharmacology 20061201 |
| Hypokalemia, cardiac failure, and reporting NXY-059 safety for acute stroke. | Journal of cardiovascular pharmacology and therapeutics 20061201 |
| The bitterest pill. | Nature 20061130 |
| Novel therapies for acute ischemic stroke. | The Israel Medical Association journal : IMAJ 20061101 |
| NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized? | Stroke 20061001 |
| On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. | Stroke 20061001 |
| NXY-059: a hopeful sign in the treatment of stroke. | Stroke 20061001 |
| Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects. | Current medical research and opinion 20060901 |
| NXY-059: brain or vessel protection. | Stroke 20060801 |
| Therapeutic strategies for the treatment of stroke. | Drug discovery today 20060801 |
| Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke. | Expert opinion on pharmacotherapy 20060801 |
| NXY-059 for acute ischemic stroke. | The New England journal of medicine 20060511 |
| NXY-059 for acute ischemic stroke. | The New England journal of medicine 20060511 |
| Is NXY-059 an advancement in the treatment of acute ischaemic stroke? | Expert opinion on pharmacotherapy 20060501 |
| Researchers focus on improving treatments for acute ischemic stroke. | JAMA 20060412 |
| Neuroprotection for acute ischaemic stroke: hope reignited. | The Lancet. Neurology 20060401 |
| Stroke - international conference 2006. | IDrugs : the investigational drugs journal 20060401 |
| NXY-059: review of neuroprotective potential for acute stroke. | The Annals of pharmacotherapy 20060301 |
| Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia. | Brain research 20060209 |
| Stroke and neurovascular protection. | The New England journal of medicine 20060209 |
| NXY-059 for acute ischemic stroke. | The New England journal of medicine 20060209 |
| The ischemic penumbra: a new opportunity for neuroprotection. | Cerebrovascular diseases (Basel, Switzerland) 20060101 |
| Other neuroprotective therapies on trial in acute stroke. | Cerebrovascular diseases (Basel, Switzerland) 20060101 |
| Reducing the burden of stroke. | Lancet (London, England) 20051119 |
| [Follow up of a contribution about treatment of acute apoplexy]. | Ugeskrift for laeger 20050808 |
| Widening the window. Strategies to buy time in treating ischemic stroke. | Scientific American 20050801 |
| Nitrone derivatives of trolox as neuroprotective agents. | Bioorganic & medicinal chemistry letters 20050615 |
| Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. | Current drug targets. CNS and neurological disorders 20050401 |
| Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. | Clinical pharmacokinetics 20050101 |
| NXY-059: a neuroprotective agent in acute stroke. | International journal of clinical practice 20041001 |
| Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies. | Experimental neurology 20040801 |
| Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. | Experimental neurology 20040801 |
| Oxygen free radical traps for the treatment of ischemia-associated organ injury. | Current opinion in investigational drugs (London, England : 2000) 20040101 |
| Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. | CNS drugs 20040101 |
| Protecting the brain: the search for a clinically effective neuroprotective drug for stroke. | Critical reviews in neurobiology 20040101 |
| Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. | Pharmacology & therapeutics 20031201 |
| NXY-059, a nitrone with free radical trapping properties inhibits release of cytochrome c after focal cerebral ischemia. | Cellular and molecular biology (Noisy-le-Grand, France) 20031201 |
| Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. | Stroke 20030901 |
| Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. | Brain research 20030516 |
| Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. | Stroke 20030201 |
| Assessment of cognitive and motor deficits in a marmoset model of stroke. | ILAR journal 20030101 |
| NXY 059: CPI 22, NXY 059G. | Drugs in R&D 20030101 |
| Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. | CNS drug reviews 20030101 |
| NXY-059. Centaur. | Current opinion in investigational drugs (London, England : 2000) 20021201 |
| In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. | Brain research 20021115 |
| Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. | European journal of clinical pharmacology 20020901 |
| NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia. | Brain research 20020830 |
| Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. | Stroke 20020601 |
| Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. | Stroke 20020501 |
| Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. | Brain research 20020405 |
| Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. | British journal of pharmacology 20020101 |
| NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. | Brain research 20010803 |
| Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059. | Free radical research 20010401 |
| Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. | Neuropharmacology 20010301 |
| Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. | Stroke 20010301 |
| NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. | Stroke 20010101 |